2014

Bariatric surgery versus intensive medical therapy for diabetes–3-year outcomes

Top

Schauer PR, Bhatt DL, Kirwan JP, et al; for the STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes–3-year outcomes. N Engl J Med. 2014. doi: 10.1056/NEJMoa1401329.

Weight-loss therapy in type 2 diabetes effects of phentermine and topiramate extended-release

Top

Exclusive! Expert diabetes blog post from Silvio Inzucchi, MD. Garvey WT, Ryan DH, Bohannan NJV, et al. Weight loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014;37(12):3309-3316.

Effect of hypoglycemia on brain structure in people with type 2 diabetes: epidemiological analysis of the ACCORD-MIND MRI trial

Top

Zhang Z, Lovato J, Battapady H, et al. Effect of hypoglycemia on brain structure in people with type 2 diabetes:  epidemiological analysis of the ACCORD MIND MRI trial. Diabetes Care. 2014;37(12):3279-3285.

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension

Top

Tikkanen I, Narko K, Zeller C, et al; for the EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2014;Epub ahead of print. DOI: 10.2337/dc14-1096.

Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh Type 2 Diabetes Study

Top

Exclusive! Expert diabetes blog post from Silvio E. Inzucchi, MD. Bedenis R, Price AH, Robertson CM, et al. Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2014. [ePub ahead of print] doi: 10.2337/dc14-0908.

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study

Top

Henry RR, Rosenstock, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2014; Epub ahead of print. DOI: 10.2337/dc13-2955.

Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes

Top

Exclusive! Expert diabetes blog post from Silvio E. Inzucchi, MD. Espeland MA, Glick HA, Bertoni A, et al; for the Look AHEAD Research Group. Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes: The Action for Health in Diabetes. Diabetes Care. 2014;37:2548-2566.

A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position

Top

Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diabetes Obes Metab. 2014;16:1041-1047.

Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012

Top

Geiss LS, Wang J, Cheng YJ, et al. Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012. JAMA. 2014;312(12):1218-1226.

Incidence of remission in adults with type 2 diabetes: The Diabetes and Aging Study

Top

Karter AJ, Nundy S, Parker MM, Moffet HH, Huang ES. Incidence of remission in adults with type 2 diabetes: The Diabetes and Aging Study. Diabetes Care. 2014; [ePub ahead of print]. doi: 10.2337/dc14-0874.

1 2 3 4 Next